RxDoctor Payments Data

Ali Hachem, MD

Hematology & Oncology · Huntsville, ALNPI 1437117157

Payments from drug & device makers

$19,877in general payments, 2019–2025

Across 1,109 payments — averaging $17.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$2K
  • AstraZeneca$1K
  • Johnson & Johnson$1K
  • Pfizer$1K
  • E.r. Squibb & Sons, L.L.C.$1K
  • Amgen$1K
  • plus $12K from 54 others

What the payments were for

  • Food & beverage$19,58699%
  • Education$2911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novartis92$1,523
AstraZeneca(2 entities)67$1,265
Johnson & Johnson(2 entities)69$1,264
Pfizer86$1,174
E.r. Squibb & Sons, L.L.C.87$1,130
Amgen66$1,014
Genentech USA, Inc.41$766
Merck35$720
Seagen Inc.52$702
Incyte Corporation25$446
Bristol Myers Squibb21$442
Eisai Inc.24$434
Daiichi Sankyo Inc.22$417
Lilly USA, LLC23$384
Regeneron Healthcare Solutions, Inc.20$362
AbbVie18$354
Astellas Pharma US Inc12$348
Dendreon Pharmaceuticals LLC11$322
Myriad Genetic Laboratories, Inc.11$312
GSK15$307
Boehringer Ingelheim13$304
Takeda Pharmaceuticals U.S.A., Inc.14$300
Sanofi15$291
Pharmacyclics LLC, An Abbvie Company19$284
Jazz Pharmaceuticals Inc.13$283
Gilead(2 entities)17$278
Bayer16$278
Exelixis Inc.11$234
Deciphera Pharmaceuticals Inc.9$188
Octapharma USA, Inc.4$185
Sobi, Inc11$184
Karyopharm Therapeutics Inc.10$173
Blueprint Medicines Corporation8$168
Beigene USA, Inc.10$167
EMD Serono, Inc.9$163
Rigel Pharmaceuticals, Inc.8$153
Geron Corporation2$150
Coherus Oncology, Inc.7$141
Pharmaessentia USA Corporation5$135
Tersera Therapeutics LLC7$134
Array Biopharma Inc8$133
Stemline Therapeutics Inc.6$133
Janssen Scientific Affairs, LLC5$132
Servier Pharmaceuticals LLC7$110
AVEO Pharmaceuticals, Inc.5$89
Pharmacosmos Therapeutics Inc.4$86
Ipsen Biopharmaceuticals, Inc4$77
Kyowa Kirin, Inc.4$77
Global Blood Therapeutics, Inc.4$68
Immunocore Limited2$62
Mirati Therapeutics, Inc.3$62
Puma Biotechnology, Inc.3$54
Recordati_rare_diseases_inc.3$44
Alnylam Pharmaceuticals Inc.2$43
Genmab U.S., Inc.2$41
Heron Therapeutics, Inc.1$41
Iovance Biotherapeutics, Inc.2$41
Lexicon Pharmaceuticals, Inc.3$40
Biocompatibles, Inc.2$40
Beone Medicines USA, Inc.2$39

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,877 in reported general payments places this provider in the 55th percentile of 177 hematology & oncology providers in Alabama.

See all hematology & oncology providers in Alabama

Medicare billing

Part B allowed, 2024
$5,497,504
Medicare patients
919
Services billed
283,707

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide88$1,237,757
RevlimidLenalidomide26$422,060
WeliregBelzutifan11$339,337
OjjaaraMomelotinib Dihydrochloride11$294,585
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5042$231,553
IbrancePalbociclib15$229,016
JakafiRuxolitinib Phosphate13$207,779
InlytaAxitinib11$174,635
VenclextaVenetoclax25$147,269
GammakedImmune Globul G/Gly/Iga Avg 4624$112,704
EliquisApixaban134$104,166
XareltoRivaroxaban72$73,647
Abiraterone Acetate16$20,017
Repatha SureclickEvolocumab16$13,218
Imatinib Mesylate13$12,168

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi$348$1,237,75788 claims
PfizerIbrance, Inlyta, Eliquis$1,174$507,817160 claims
Bristol Myers SquibbRevlimid$442$422,06026 claims
MerckWelireg$720$339,33711 claims
GSKOjjaara$307$294,58511 claims
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$300$231,55342 claims
Incyte CorporationJakafi$446$207,77913 claims
AbbVieVenclexta$354$147,26925 claims
Johnson & JohnsonXarelto$1,264$73,64772 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$132$20,01716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 177 hematology & oncology providers in Alabama.

Other hematology & oncology in Huntsville

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →